Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Craig Hettenbach from Morgan Stanley downgraded the rating on the stock to a Hold and gave it a $60.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Craig Hettenbach’s rating is based on a combination of factors suggesting that while Hims & Hers Health presents a compelling growth narrative, there are considerations for investors to ponder before committing further. The company showcases a differentiated and scalable platform, high gross margins, and strong leadership, all of which are positive indicators. However, the recent significant outperformance of the stock raises expectations and presents a higher bar for near-term results.
Moreover, the potential volatility surrounding GLP-1 developments introduces both risks and opportunities, which may influence stock performance. The Hold rating reflects a disciplined investment approach, acknowledging the company’s solid business momentum and the possibility of future entry points becoming more attractive. The increase in the price target to $60 is underpinned by a higher EV/S multiple, recognizing the business’s increasing momentum and comparative valuation expansion.